Lab21 appoints group director

Of quality, regulatory affairs and operations excellence

Lab21, a global specialist in personalised medicine and clinical diagnostics, has appointed Fraser Logue as group director of quality, regulatory affairs and operations excellence based Cambridge in the UK.

Dr Logue worked for almost two decades in divisions of Abbott Laboratories. He was most recently division vice president World Wide Manufacturing for Abbott Diabetes Care, moving from division vice president European Operations. Prior to this he was operations director for Abbott Diagnostics Division Ireland, and director of Quality & Regulatory and marketing manager for Abbott Diagnostics Division in Germany.

Dr Logue said: ‘Lab21 has achieved remarkable progress within the past 4 years, growing five times in size. I am looking forward to contributing to its future success.’

You may also like

Research & Development

Lab21 to develop cancer diagnostic assay with leading pharma company

Onconostica product to be launched later this year
Finance

Lab21 acquires Myconostica

Expands growing proprietary diagnostic portfolio
Research & Development

Lab21 secures new patents

Portfolio grows in Hepatitis C drug resistance and fluorescent carbon-based nanoparticle technology
Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
You need to be a subscriber to read this article.
Click here to find out more.
Analysis
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)

Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)

Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence
Regulatory
Leica Biosystems brings Tempus pathology products to Aperio AI Store

Leica Biosystems brings Tempus pathology products to Aperio AI Store

Expanding the Aperio AI Store gives researchers more ways to study cancer through AI-enabled tools within a connected digital pathology ecosystem
You need to be a subscriber to read this article.
Click here to find out more.
Analysis
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)

Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)

As biologics become increasingly complex, demonstrating consistent biological activity at lot release is essential. Yet the cell-based assays used to measure potency introduce significant challenges in standardisation, reproducibility and regulatory compliance
Subscribe now